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OBJECTIVES The goal of this study was to compare the relative efficacy of an angiotensin-converting
enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) in suppressing the
histopathologic changes that lead to ventricular remodeling after an acute myocardial
infarction (AMI).
BACKGROUND Myocardial interstitial fibrosis in the noninfarcted region is a major histologic landmark
resulting in cardiac dysfunction after AMI. However, the relative potency of an ACE
inhibitor and ARB on suppressing the histopathologic changes was unclear.
METHODS Rats with AMI were randomized to fosinopril, valsartan or a combination of the two drugs
for two or four weeks. The total, type I and type III collagen and activated fibroblasts and
macrophages were quantified by histomorphometry. The expression of transforming growth
factor-beta 1 (TGF-beta 1) messenger ribonucleic acid (mRNA) was determined by reverse
transcription polymerase chain reaction.
RESULTS Acute myocardial infarction resulted in significant elevation of total (p , 0.001) and type I
(p , 0.001) collagen and a twofold increase in TGF-beta 1 mRNA expression (p , 0.001)
in the septum at two and four weeks. Macrophages and activated myofibroblasts infiltrated
extensively in the infarct zone. Treatment with valsartan or combination therapy normalized
the total and type I collagen (p , 0.001) as well as TGF-beta 1 mRNA level (p , 0.01) in
the septum and was associated with the suppression of macrophages and myofibroblasts in the
infarct zone (p , 0.01). Fosinopril was less effective than valsartan or combination therapy.
CONCLUSIONS The use of valsartan, especially combined with fosinopril, was more effective than fosinopril
in the suppression of histopathologic changes resulting in cardiac remodeling after AMI. This
study has important therapeutic implications in pharmacotherapy of clinical practice. (J Am
Coll Cardiol 2001;38:1207–15) © 2001 by the American College of Cardiology
Myocardial remodeling after acute myocardial infarction
(AMI) is a process of progressive left ventricular (LV)
dilation that contributes to the development of cardiac
failure and late mortality (1). It not only involves the infarct
zone, but the noninfarct region is also potentially affected.
Treatment with angiotensin-converting enzyme (ACE) in-
hibitors attenuates LV remodeling and improves prognosis
in patients with significant LV dysfunction after an AMI
(2). However, the therapeutic efficacy of ACE inhibitors
may be limited by the ACE escape phenomenon due to
non-ACE-dependent pathways of angiotensin II produc-
tion (3). It implicates the potential usefulness of combined
ACE inhibitor and angiotensin II type 1 receptor blocker
(ARB) after AMI.
To date, the pathogenic mechanisms that govern LV
remodeling are not entirely clear. In animal models and
patients with AMI, LV modeling is accompanied by the
accumulation of myocardial interstitial collagen in the non-
infarcted region of the heart (4,5). This was suppressed by
either an ACE inhibitor or ARB (6,7). However, the
stimuli that result in histopathologic changes are not fully
understood. In pathologic fibrosis seen in LV hypertrophy,
infiltration of activated myofibroblasts and possibly other
inflammatory cells has been shown to play a pivotal role (8).
In the infarct zone with fibrosis and scarring, an inflamma-
tory process has been proposed that is characterized by
numerous inflammatory cellular infiltration (9). The activa-
tion of interstitial or inflammatory cells and the subsequent
deposition of interstitial collagen are likely mediated
through transforming growth factor-beta 1 (TGF-beta 1),
the fibrogenic cytokine (10). We hypothesized that, in the
pathogenic process of myocardial interstitial fibrosis in the
noninfarcted region, inflammatory cellular infiltration
might play a role either to act locally or in a paracrine
fashion through the production of TGF-beta 1. The aims of
this study were to investigate whether: 1) local infiltration of
macrophages and activated myofibroblasts played a role in
the myocardial interstitial fibrosis in the noninfarcted region
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of the heart after AMI; 2) TGF-beta 1 was involved in
interstitial fibrosis; 3) type I or type III collagen was
involved in interstitial fibrosis; 4) the above changes were
suppressed by an ACE inhibitor, ARB or a combination of
the two drugs; and 5) ARB-based therapy was more
effective than ACE inhibitor on the suppression of these
pathogenic changes.
METHODS
Animal preparation. Ten-week-old male Sprague-Dawley
rats (SDr) were used. They were housed at 23 to 25°C in a
12:12-h light-dark cycle with ad libitum food and water.
Blood pressure and pulse were measured weekly by nonin-
vasive tail occlusion cuff system (model 221, IITC Inc. Life
Science Instruments, Woodland Hills, California) with
computerized blood pressure monitor (model 31, IITC Inc.
Life Science Instruments) (11). The measurement was
performed in a slightly restrained, prewarmed room tem-
perature. At least two measurements at steady-state were
performed and the averaged value was taken. Acute myo-
cardial infarction was induced by left coronary artery liga-
tion as described previously (12). Briefly, SDr were anes-
thetized by intraperitoneal injection of katamine (50 mg/kg)
and xylazine (10 mg/kg). They were intubated, ventilated
and left thoracotomy was performed at the fifth and sixth
ribs. The left coronary artery was ligated at approximately
3 mm from its origin by a 5.0 silk suture. Sham-operated
rats underwent the same operation but, without coronary
artery ligation, served as controls. The animal experiments
were approved and performed according to the regulation of
the Animal Ethics Committee of the University of Hong
Kong.
Experimental protocol. Twenty-four hours after AMI, the
rats were randomized to one of the four groups: no
treatment, ACE inhibitor by fosinopril (3 mg/l drinking
water and the daily consumption per rat was 10 to 12 ml),
valsartan (30 mg/day/kg by gavaging) and a combination of
both drugs for two or four weeks (10 to 12 rats in each
group). The dosage of these drugs was previously found to
exert an antifibrotic effect in other organs in rats (13), and
the timing of the commencement of the drugs will simulate
a clinical situation after AMI. When the rats were sacrificed,
half of the animals hearts were cut into four slices, fixed in
ice cold 10% buffered formalin (pH 7.4), dehydrated
through alcohol gradient and embedded in paraffin for
sectioning. The other half of the hearts was snap frozen in
liquid nitrogen for protein and RNA extraction.
Reverse transcription polymerase chain reaction (RT-
PCR). Frozen tissue samples were homogenized and ribo-
nucleic acid (RNA) was extracted by acid-phenol-
guanidinium-thiocyanate method (14). Gene expressions
were detected by RT-PCR. The complementary deoxyribo-
nucleic acid (cDNA) was synthesized by the superscript II
first strand cDNA preamplification system (Gibco BRL,
Rockville, Maryland) and subsequently used for polymerase
chain reaction (PCR) amplification. Thirty cycles of PCR
for TGF-beta 1 and beta-actin were preformed at 94°C for
1 min, 57°C for 1 min and 72°C for 1 min. The primers
used were: TGF-beta 1, 59 GAA GCC ATC CGT GGC
CAG AT 39 (forward) and 59CCA GTG ACG TCA AAA
GAC AG 39 (backward); beta-actin: 59-CCT TCC TGG
GTA TGG AAT CCT-39 (forward) and 59GGA GCA
ATG ATC TTG ATC TT 39 (backward). The levels of
messenger RNA (mRNA) expression were quantified by the
UV-gel documentation system (BioRad, Hercules, Califor-
nia).
Morphometric measurement. Morphometric measure-
ments were done by systematically scanning the regions
using a Zeiss Axiophot microscope at a magnification of
2003 by an investigator blinded to the groups. Every fifth
field in the septum and every third field in the right ventricle
were sampled for analysis. Fields containing vessels, artifacts
or incomplete tissue were excluded. Each image was ana-
lyzed using hue, saturation and intensity detection mode of
Leica Qwin Image Analyzer (Leica, United Kingdom)
under standardized brightness and contrast according to the
user manual of the software. Mean values of at least 15 fields
were taken in each region of the heart for the following
experiments.
Total collagen staining. Total collagen was stained with
sirius red (15). Five-mm paraffin sections from each slice
were treated with 0.2% phosphomolydic acid for 5 min and
then immersed in 0.1% sirius red solution for 90 min. After
washing in 0.01N HCl for 2 min, the sections were
dehydrated and mounted. Morphometric analysis for total
collagen was calculated by dividing the sum area of the
positively stained sirius red and the sum of the reference area
multiplied by 100 (15).
Immunohistochemistry. Detection of various tissue anti-
gens was performed by the avidin-biotin-enzyme complex
peroxidase method as previously described (11). The pri-
mary antibodies used were ED1 for macrophages (1:1000,
Serotec, Oxford, United Kingdom) (16), alpha-smooth
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
alpha-SMA 5 alpha-smooth muscle actin
AMI 5 acute myocardial infarction
ANOVA 5 analysis of variance
ARB 5 angiotensin receptor blocker
AT1R 5 angiotensin II type 1 receptors
AT2R 5 angiotensin II type 2 receptors
cDNA 5 complementary deoxyribonucleic acid
LV 5 left ventricle/left ventricular
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1208 Yu et al. JACC Vol. 38, No. 4, 2001
Cellular Infiltration and Myocardial Fibrosis After AMI October 2001:1207–15
muscle actin (alpha-SMA) for fibroblasts (1:2500, DAKO,
Carpinteria, California) (17) as well as type I and III
collagen (1:2500 and 1:3000, Chemicon, Temecula, Cali-
fornia). Positive signals were visualized by Vectastain Elite
ABC Kit (Vector Lab, Burlingame, California) using 3,39-
diaminobenzidine tetra-hydrochloride (Sigma Immuno
Chemicals, St. Louis, Missouri) as a chromogen. The
number of macrophages and activated myofibroblasts were
quantified by counting the total number of positively stained
ED1 or alpha-SMA cells in 20 grid fields with a total area
of 0.1 mm2. The amount of collagen type I and III was
quantified by Lica Qwin image analyzer and expressed in
percents as described before.
Assessment of infarct size. Each ventricle was cut into
four horizontal slices and stained with sirius red for scar
tissue. Using the same histomorphometric technique, the
infarct size was calculated as mean percentage infarct area
relative to the LV cross-sectional area at a magnification of
403.
Statistical analysis. The differences in mean value of the
various treatment groups were analyzed by Scheffe’s multi-
ple comparisons in one-way analysis of variance (ANOVA)
(SPSS for Windows, version 7.5, SPSS Inc., Chicago,
Illinois). The interaction of drug treatment and treatment
period was analyzed by two-way ANOVA. The comparison
of parametric variables between two and four weeks was
performed by unpaired sample t test. A regression analysis
was performed to correlate the amount of cellular infiltra-
tion and collagen. All the data were expressed as mean 6
SD. A p value ,0.05 was considered statistically significant.
RESULTS
The mortality of the procedure was 40%. There was no late
death in all groups during the study period. At baseline and
at the end of the study, there was no difference in body
weight or heart rate between AMI and sham-operated rats
(Table 1). However, the blood pressure was significantly
lower after fosinopril or valsartan therapy and was further
reduced by combination therapy. There was no difference in
infarct size between AMI and various treatment groups
(Table 1).
Collagen volume fraction. Without treatment the colla-
gen volume fraction for total collagen increased twofold in
the noninfarcted septum at two and four weeks after AMI
(Table 2). Treatment with fosinopril only partially de-
creased the collagen content (p , 0.01). However, both
valsartan and combination therapy completely prevented
pathologic collagen deposition after AMI (p , 0.001).
There was no difference between two and four weeks of
therapy. In the right ventricle, there was a trend of increase
in collagen content at two and four weeks after AMI, which
was significantly decreased by combination therapy (both
p , 0.01) (Table 2).
For the specific subtype of collagen, there was a signifi-
cant increase in type I collagen in the septum two and four
weeks after AMI when compared with sham (p , 0.001).
Treatment with either drug decreased the type I collagen
content at both time points when compared with AMI rats
(p , 0.001). In addition, combination therapy resulted in
the lowest content of type I collagen and was significantly
lower than fosinopril-treated rats at two weeks (p , 0.01).
Valsartan therapy also resulted in a lower type I collagen
content than fosinopril therapy for two weeks (p , 0.01)
(Table 2). For the type I collagen content in the right
ventricle, there was a trend of increase after AMI, which
was significantly reduced only by combination therapy (p ,
0.01). There was no difference in treatment effect between
two and four weeks for type I collagen. The type III collagen
contents in both the septum and right ventricle showed a
trend of increase after AMI, which was reduced by combi-
Table 1. Comparison of Body Weight, Blood Pressure and Heart Rate in Different Groups of Rats Before Acute Myocardial
Infarction and at the End of Study Period
Sham
(n 5 20)
AMI
(n 5 24)
Fosinopril
(n 5 22)
Valsartan
(n 5 24)
Combination
Therapy
(n 5 22)
Baseline
BW (g) 365 6 30 373 6 31 398 6 27 362 6 13 376 6 23
SBP (mm Hg) 118 6 12 124 6 14 125 6 10 118 6 10 123 6 9
DBP (mm Hg) 89 6 12 95 6 18 102 6 13 99 6 11 102 6 8
MBP (mm Hg) 98 6 13 100 6 9 96 6 11 97 6 9 95 6 12
HR (beats/min) 383 6 20 388 6 9 395 6 20 397 6 10 392 6 22
Postinfarction
Body weight (g) 395 6 48 411 6 50 407 6 32 392 6 12 396 6 36
SBP (mm Hg) 113 6 12 107 6 14 99 6 11* 95 6 12* 87 6 10†‡
DBP (mm Hg) 97 6 14 88 6 13 83 6 11* 78 6 13* 68 6 11†‡
MBP (mm Hg) 102 6 13 95 6 13 89 6 10* 84 6 12* 74 6 11†‡
HR (beats/min) 375 6 24 388 6 23 398 6 21 381 6 21 395 6 48
Infarct size (%) — 22.6 6 9.1% 18.6 6 8.4% 20.7 6 8.1% 18.0 6 7.2%
*p , 0.05 vs. sham-operated rats; †p , 0.001 vs. sham-operated rats; ‡p , 0.01 vs. AMI rats.
AMI 5 acute myocardial infarction; BW 5 body weight; DBP 5 diastolic blood pressure; HR 5 heart rate; MBP 5 mean blood pressure; SBP 5 systolic blood pressure.
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nation therapy. There was a significant difference in treat-
ment effect between two and four weeks in the septum (p ,
0.05) (Table 2).
Inflammatory cellular infiltration. Macrophage or acti-
vated myofibroblast was not found in the myocardial inter-
stitium of the noninfarcted septum and the right ventricle or
the sham-operated rats (Table 3). In rats with AMI, there
was significant infiltration of activated myofibroblasts and
macrophages in the infarcted LV free wall, which were not
seen in sham-operated rats. Two and four weeks after
treatment with either fosinopril, valsartan or combination
therapy there was a significantly decreased number of
activated myofibroblasts in the infarct zone, though combi-
nation therapy was better than fosinopril alone (Fig. 1). On
the other hand, only valsartan and combination therapy
decreased the number of macrophages in the infarct zone
(Table 3). After four weeks of therapy, the number of
macrophages was significantly lower than it was at two
weeks (p , 0.01), though the number of activated myofi-
broblasts remained comparable. There was a positive corre-
lation between the amount of macrophages and type I
collagen in the septum (r 5 0.46, p 5 0.001) but not the
amount of activated myofibroblasts (r 5 0.02, p 5 NS). The
number of macrophages and activated myofibroblasts also
modestly correlated with each other (r 5 0.30, p 5 0.002).
TGF-beta 1 mRNA expression. The TGF-beta 1 mRNA
expression was increased 2.5-fold in the noninfarcted sep-
tum at two and four weeks after AMI (p , 0.001) (Table 3,
Fig. 2). Treatment with valsartan or combination therapy,
not fosinopril, significantly reduced its expression in the
control level. In the right ventricle, there was only mild
elevation of TGF-beta 1 mRNA after AMI, which was
unaffected by drug therapy. There was no difference in
treatment effect when compared by treatment duration.
DISCUSSION
This study illustrated the relationship between inflamma-
tory cellular infiltration after AMI and the development of
myocardial interstitial fibrosis at the noninfarcted LV sep-
tum. The ischemic-induced myocyte necrosis probably in-
cited an inflammatory response that mediated the infiltra-
tion of macrophages and activated myofibroblasts in the
infarct zone. Despite the absence of cellular infiltration in
the septum, this site developed pathologic interstitial fibro-
sis as early as two weeks after AMI, which was mainly
attributed to the increase in gene expression of TGF-beta 1
and accumulation of type I collagen. Treatment with the
ARB-based regimens and, to a lesser extent, an ACE
inhibitor, significantly attenuated the activation and infil-
tration of inflammatory cells in the infarct zone and nor-
malized the pathophysiologic changes in the noninfarcted
septum. In the right ventricle, there was a trend, but
insignificant increase, in interstitial fibrosis and TGF-beta 1
gene expression after AMI, though combination therapy
decreased the collagen content in this region.
Inflammatory cellular infiltration and interstitial fibrosis
after AMI. It was recently hypothesized that myocyte
damage after AMI is mediated by an inflammation-like
response. In one animal study, infiltration of inflammatory
cells, such as macrophages and neutrophils, and phenotypic
transformation of fibroblasts into activated myofibroblasts
were observed in the infarct zone early after AMI (9). These
cells play an active role in mediating cellular damage and
synthesis of interstitial collagen in the infarct zone through
the activation of fibrogenic cytokines (18). However, in-
volvement of these cells in myocardial interstitial fibrosis has
not been demonstrated in the noninfarcted regions in
previous studies (4,19). A recent study using proliferating
cell nuclear antigen (PCNA) as a marker found that it was
expressed sporadically in the noninfarcted myocardium (7).
Using specific monoclonal antibodies, we confirmed the
absence of macrophages and activated myofibroblasts in the
noninfarcted septum and the right ventricle. Therefore, the
elevated PCNA observed in that study (7) without specific
cellular finger-printing is likely representing the natural
turnover of cardiac interstitial fibroblasts (nonactivated
ones). Since activated cells with cytokine production are
known to act in an autocrine and paracrine fashion, it is
possible that cells infiltrated in the infarct zone acted as a
source of fibrogenic cytokine production, which stimulated
the extracellular matrix production in a local and paracrine
manner. This hypothesis was also indirectly supported by
the observation that reducing the inflammatory infiltrates in
the infarct zone by an ACE inhibitor or ARB also normal-
ized TGF-beta 1 gene expression and interstitial fibrosis in
the septum and the right ventricle, and a positive correlation
exists between the number of macrophages and the amount
of interstitial fibrosis. The anti-inflammatory action of
ACE inhibitors had been suggested in the rat model of renal
tubulointerstitial fibrosis, in that reduction of interstitial
cellular infiltrates as well as tubular immunoglobulin and
complement reactivity was demonstrated after four weeks of
treatment (20). This might work through suppression of
inflammatory mediators such as the adhesion molecules,
which has been suggested in human atherosclerosis (21). It
is important to note that myocytes or cells other than those
investigated in this study may contribute to the expression
of fibrogenic cytokines (22).
Collagen deposition in the noninfarct zone after AMI.
Disproportional increase in type I collagen in the heart
results in increased chamber stiffness and reduced ventric-
ular compliance (23). Although a few studies had demon-
strated the increase in total interstitial collagen in the
noninfarcted region of the LV after AMI, the change in
collagen composition was not entirely clear (4–7,19). Our
study has shown that the type I, but not type III, collagen
was increased in the septum and, to a lesser extent, in the
right ventricle. This may represent an important structural
basis in cardiac remodeling after AMI in which chamber
dilation and myocardial dysfunction occur (1).
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Effect of ACE inhibitors or ARBs on ultrastructural
remodeling. Activation of cardiac ACE has been demon-
strated in the site of interstitial fibrosis after AMI (24). In
addition, angiotensin II has been shown to induce fibroblast
proliferation and increased collagen synthesis, while angio-
tensin II type 1 receptors (AT1R) have been identified on
cultured cardiac fibroblasts (25,26). These observations
suggest that activation of the renin-angiotensin system play
Figure 1. Immunolocalization of activated cardiac myofibroblasts (A to E) and macrophages (F to J) in the infarct region two weeks after acute myocardial
infarction (AMI). The activated myofibroblasts and macrophages were stained dark brown by anti-alpha-smooth muscle actin and anti-ED-1 antibodies,
respectively. There was significant infiltration of activated myofibroblasts (B) and macrophages (G) after AMI that were not seen in the sham-operated rats
(A and F). Treatment with fosinopril (C) decreased the infiltration of activated myofibroblasts, but not the macrophages (H). On the other hand, valsartan
(D and I) and combined therapy of fosinopril and valsartan (E and J) significantly reduced the number of activated myofibroblasts and macrophages in the
infarct zone (magnification 4003).
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a key role in interstitial fibrosis. Previous studies using other
ACE inhibitors or ARBs as treatment from four weeks to
one year significantly reduced interstitial collagen
(4,6,19,27). We confirmed and extended these observations
by demonstrating that treatment with ARB-based regimens
and, to a lesser extent, an ACE inhibitor, for as short as two
weeks after AMI normalized myocardial interstitial fibrosis
in the noninfarcted regions of the heart. In addition, we
provide new data that the normalization of myocardial
fibrosis was largely due to the decrease in type I collagen,
but not type III. In accordance with the changes in collagen
volume fraction, the expression of TGF-beta 1 mRNA was
also reduced more effectively by ARB-based regimens.
Therefore, valsartan is superior to fosinopril in the suppres-
sion of interstitial collagen deposition, while a combination
of the two agents seems to confer the best benefit. In fact,
there was a suggestion that the ACE inhibitor captopril
only reduces myocardial hypertrophy but is unable to
decrease myocardial collagen content after AMI (28). Two
previous studies compared the effect of enalapril and losar-
tan on the suppression of interstitial fibrosis in the nonin-
farcted LV and reported a similar efficacy between the two
drugs (4,7). The difference between this study and others
might be related to the difference in pharmacokinetics
between agents of the same class, difference in the degree of
tissue penetration and difference in route of administration.
In this study, the infarct size was not different in various
treatment groups. This is expected, as therapy was only
commenced 24 h after AMI. However, this model simulates
our clinical practice, that an ACE inhibitor was only started
after AMI. Unlike ischemic-reperfusion models in which
infarct size was reduced by ACE inhibitors or ARBs that
commenced before surgery (29), no reduction in infarct size
was observed in the AMI models (30). The LV mass and
function was not measured in this study and, therefore, the
relationship between infarct size and extent of cardiac
dysfunction was not known.
The additional benefit of combination therapy over fosi-
nopril alone is likely to confirm the previous hypothesis that
ACE inhibitors act mainly by enhancing the beneficial
Figure 2. Transforming growth factor-beta 1 (TGF-beta 1) messenger ribonucleic acid (mRNA) expression in different regions of the heart two weeks after
acute myocardial infarction (AMI). Reverse transcription polymerase chain reaction was performed for RNA extracted from noninfarcted septum of the left
ventricle and the right ventricle after AMI. In the noninfarcted septum, there was about twofold increase in TGF-beta 1 mRNA after AMI. Treatment
with fosinopril (Fos) significantly decreased the amount of TGF-beta 1 mRNA expression in this region, while valsartan or a combination of fosinopril and
valsartan (Fos 1 Val) normalized its expression. In the right ventricle, there was no significant change in TGF-beta 1 mRNA in any group. M 5
fX174/HaeIII marker; Sham 5 sham-operated rats.
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action of bradykinin rather than by suppressing angiotensin
II production (31). From our results, it appeared that
antagonizing the binding of angiotensin II to its AT1R was
a more promising cardioprotective mechanism after AMI.
In the canine model of ischemic reperfusion, the cardiopro-
tective effect of AT1R antagonist was found to involve the
upregulation of angiotensin II type 2 receptors (AT2R) (32).
In fact, a recent study has shown that the benefits of ACE
inhibitors and ARBs on LV remodeling were blocked by a
bradykinin receptor antagonist and AT2R antagonist, re-
spectively (33). The clinical benefit of ARBs might be
particularly relevant in clinical practice as the expression
level of AT2R is much higher in human hearts than it is in
rodent hearts so that the AT2R-mediated actions are likely
enhanced, such as the antiproliferative effect (34). Whether
the observed advantage of valsartan on structural damages
in animal models of AMI can be transformed into clinical
benefit needs to be confirmed by the large, ongoing
VALIANT trial (VALsartan In Acute myocardial iNfarc-
tion Trial).
In conclusion, AMI resulted in accumulation of type I
myocardial interstitial collagen in the noninfarcted septum
secondary to activation of TGF-beta 1 mRNA. Infiltration
macrophages and activated myofibroblasts from the infarct
zone are likely to play a paracrine role in these pathologic
changes. Combination therapy with valsartan and fosinopril
is more effective than fosinopril alone in the attenuation of
these pathologic changes. The results might have therapeu-
tic implication in the prevention of cardiac remodeling after
AMI.
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